Free Trial

CREDIT UPDATE: Pfizer (PFE: A2/A): Hospital Drug sale

CREDIT UPDATE
  • Reuters reporting that Pfizer (under pressure from Starboard) may sell its Hospital Drugs unit
  • Currently generates $500m of EBITDA
  • Entire company's EBITDA is c.19.7bn so about 2.5% of total
  • Likely to be worth low single digits billions.
  • We would need to know what the proceeds would be used for to decide on the reaction but it is not huge.
56 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Reuters reporting that Pfizer (under pressure from Starboard) may sell its Hospital Drugs unit
  • Currently generates $500m of EBITDA
  • Entire company's EBITDA is c.19.7bn so about 2.5% of total
  • Likely to be worth low single digits billions.
  • We would need to know what the proceeds would be used for to decide on the reaction but it is not huge.